Publications by authors named "Warren Ramesh"
Guidance for Administering Biologics for Severe Asthma and Allergic Conditions.
Can Respir J
September 2022
Article Synopsis
- Asthma is a common condition in Canada that may require biologic treatments, but misconceptions about their safety during COVID-19 lead to inappropriate discontinuation of these therapies.
- Biologics can generally be safely continued during respiratory infections and are beneficial in managing severe asthma amidst concerns about cardiac issues.
- This guidance document emphasizes the importance of maintaining asthma control, the safe administration of vaccines with biologic treatments, and appropriate screening for respiratory illnesses to minimize health risks during the pandemic.
Rationale: Pulmonary rehabilitation improves dyspnea and exercise capacity in idiopathic pulmonary fibrosis (IPF); however, it is unknown whether breathing high amounts of oxygen during exercise training leads to further benefits.
Objectives: Herein, we describe the design of the High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated with Nintedanib study (the HOPE-IPF study). The primary objective of this study is to determine the physiological and perceptual impact of breathing high levels of oxygen during exercise training in patients with IPF who are receiving antifibrotic therapy.
Rationale: Small studies have suggested that inhaled corticosteroids can suppress systemic inflammation in chronic obstructive pulmonary disease (COPD).
Objectives: To determine the effect of inhaled corticosteroids with or without long-acting beta(2)-adrenergic agonist on systemic biomarkers of inflammation.
Methods: We conducted a double-blind randomized placebo-controlled trial across 11 centers (n = 289 patients with FEV(1) of 47.
Background: Systemic inflammation is associated with various complications in chronic obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and cardiovascular diseases. Inhaled corticosteroids attenuate airway inflammation, reduce exacerbations, and improve mortality in chronic obstructive pulmonary disease. Whether inhaled corticosteroids by themselves or in combination with a long-acting beta2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown.
View Article and Find Full Text PDF